This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Carcinoma, Hepatocellular
and you are
over 18
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs. CyberKnife SBRT 2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC 3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.

Provided treatments

  • Device: CyberKnife
  • Procedure: TACE
  • Drug: CT Contrast
  • Drug: doxorubicin
  • Drug: Epirubicin
  • Drug: 5-fluorouracil
  • Drug: Mitomycin C
  • Drug: Gemcitabine
  • Drug: Cisplatin
  • Device: SMANCS

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01327521. The sponsor of the trial is Albert Koong and it is looking for 0 volunteers for the current phase.
Official trial title:
International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma